CheckCausesObesity.com Launches Screening

A new online tool called CheckCausesObesity.com has been launched to systematically screen for the many potential causes of obesity. The tool was developed by a multidisciplinary team of experts and aligns with international clinical guidelines.

The platform, referred to as CCO, is designed to support both individualized patient assessment and broader population-level monitoring. It moves beyond a simple focus on weight or body mass index. Instead, it prompts a comprehensive review across seven distinct categories of contributing factors.

A Comprehensive Screening Framework

CCO systematically evaluates potential obesity causes and contributing factors. The screening covers lifestyle and medical factors. It also reviews selected comorbidities, anthropometric measurements, and demographic and socioeconomic characteristics.

This structured approach aims to ensure no potential cause is overlooked during a clinical assessment. The developers state the tool is based on the latest scientific evidence.

Development and Validation

The tool's development involved contributions from numerous specialists. Professor E. Feskens and her team of nutritional scientists from Wageningen University & Research helped develop validated dietary questions for the platform.

Other contributors included public health researchers, health IT specialists, information managers, and a Chief Medical Information Officer from Erasmus University Medical Center. They provided support with data analysis and management. The work received support from the non-profit Elisabeth Foundation.

Potential Applications in Care

For healthcare providers, CCO offers a standardized method to investigate obesity in adults. It can guide a more personalized treatment plan by identifying specific underlying or contributing issues for each patient.

The tool's creators also envision its use for monitoring obesity trends and causes across larger populations. This could inform public health strategies.

Several authors of the report disclosed competing interests related to obesity research and education. Elisabeth F.C. Van Rossum is a member of an Endocrine Society guideline committee and chairs Dutch obesity groups. She reports speaker fees from various academic and medical education organizations. Both van Rossum and M.R. Boon receive royalties from a book about fat. Boon also received honoraria for independent lectures from several entities, including Eli Lilly. E.L.T. Van den Akker reports speaker fees and is a principal investigator for drug trials funded by Rhythm Pharmaceuticals.